Teachers Advisors LLC held its position in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) during the fourth quarter, Holdings Channel reports. The firm owned 26,961 shares of the specialty pharmaceutical company’s stock at the end of the fourth quarter. Teachers Advisors LLC’s holdings in Adamas Pharmaceuticals were worth $456,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in Adamas Pharmaceuticals during the fourth quarter valued at $469,000. Dimensional Fund Advisors LP increased its position in Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock valued at $2,138,000 after buying an additional 28,994 shares during the last quarter. State Street Corp increased its position in Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock valued at $4,356,000 after buying an additional 15,216 shares during the last quarter. Opaleye Management Inc. increased its position in Adamas Pharmaceuticals by 14.0% in the fourth quarter. Opaleye Management Inc. now owns 285,000 shares of the specialty pharmaceutical company’s stock valued at $4,817,000 after buying an additional 35,000 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Adamas Pharmaceuticals during the fourth quarter valued at $9,058,000. Institutional investors and hedge funds own 75.72% of the company’s stock.
Shares of Adamas Pharmaceuticals, Inc. (ADMS) opened at 17.49 on Friday. The company’s market capitalization is $391.06 million. Adamas Pharmaceuticals, Inc. has a 12 month low of $12.10 and a 12 month high of $19.50. The stock’s 50 day moving average is $16.46 and its 200 day moving average is $16.63.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.72). Adamas Pharmaceuticals had a negative net margin of 10,499.65% and a negative return on equity of 45.19%. During the same period in the previous year, the company posted ($0.65) earnings per share. On average, equities analysts predict that Adamas Pharmaceuticals, Inc. will post ($3.47) EPS for the current fiscal year.
Several research analysts have weighed in on the stock. Mizuho reiterated a “buy” rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, February 28th. Cowen and Company reiterated an “outperform” rating and issued a $45.00 price target on shares of Adamas Pharmaceuticals in a research report on Sunday, May 28th. Finally, Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $28.50.
In other Adamas Pharmaceuticals news, CEO Gregory T. Went sold 2,807 shares of the company’s stock in a transaction on Tuesday, March 21st. The shares were sold at an average price of $17.03, for a total transaction of $47,803.21. Following the completion of the transaction, the chief executive officer now directly owns 166,526 shares in the company, valued at $2,835,937.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 4,256 shares of company stock valued at $72,480 over the last 90 days. 29.00% of the stock is currently owned by company insiders.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/teachers-advisors-llc-continues-to-hold-stake-in-adamas-pharmaceuticals-inc-adms/1916919.html
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.